Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalcetrapib in Patients With Stable Coronary Heart Disease or at Elevated Cardiovascular Risk
NCT01516541Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2012
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of dalcetrapib in cardiovascular disease (CVD), coronary heart disease (CHD), dyslipidemia, Peripheral Arterial Disease (PAD), sponsored by Roche. Started Jan 2012; status: completed.
02
Drugs
dalcetrapib
03
Conditions
cardiovascular disease (CVD)coronary heart disease (CHD)dyslipidemiaPeripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT01516541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01516541.